Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

Inclusion Criteria: * Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and/or blood tests hospitalized between 1st of January 2018 and 31st of December 2022. * Evidence of ascites due to portal hypertension * Clinical suspicion of HRS-AKI or HRS-AKI-like syndrome (in case of previously diagnosed CKD) * Pre-existing data on kidney function (SCr and eGFR) minimum 3 months prior to admission in a stable situation * Dip stick urine test results (screening for proteinuria and hematuria) before initiation of AKI-treatment * Vasoactive treatment for the management of HRS-AKI, as defined by the administration of terlipressin or noradrenalin plus albumin * Age ≥ 18 years old Exclusion Criteria: * Uncontrolled shock * Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (ischemic cardiomyopathy, hypertensive cardiomyopathy, etc.) * Patients with hepatocellular carcinoma BCLC C or D * Patients receiving renal replacement therapy at baseline